What can a cure cost?
It’s hard to put a price tag on a medical cure, particularly when it comes to gene therapies. To receive appropriate returns on investment, developers are demanding up to €1.9m per patient for what they say are ‘one-time’ treatments. Gene therapy experts and payors are sceptical. Outcome-based pricing is one approach to discovering the true value of a therapy to the patient collective. However, pharma companies that can’t count on high up-front payments are taking a bigger risk.
In this issue:
- Financing: How sustainability is integrated into biotech investments
- Industrial Biotech: Companies target consumer markets with innovations at EFIB
- AMR: A new IMI initiative seeks to reincentivise antibiotics R&D